Physician profile
Wei Xu
NPI 1932251931
$7,404.96
in general payments reported to CMS, 2019-2025
23 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $330 · 2021: $774 · 2022: $662 · 2023: $1,135 · 2024: $2,121 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,519 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,518.93 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,027.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,189.33 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $1,052.12 | 2019-2025 | Vemlidy, Livdelzi, Yeztugo |
| Abbott Laboratories | $341.21 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $226.28 | 2023-2024 | |
| Abbvie INC. | $163.70 | 2019-2021 | |
| Horizon Therapeutics Plc | $125.54 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Noven Pharmaceuticals, INC. | $124.99 | 2024 | Xelstrym |
| Ascensia Diabetes Care US INC. | $123.24 | 2023 | |
| Pfizer INC. | $121.37 | 2019 | |
| Lilly USA, LLC | $117.54 | 2024-2025 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $105.67 | 2023-2025 | Myrbetriq, Veozah |
| Amgen INC. | $104.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $90.11 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $87.64 | 2020 | |
| Genentech USA, INC. | $85.15 | 2019 | |
| Exact Sciences Corporation | $82.83 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.63 | 2019-2023 | Jardiance |
| Allergan, INC. | $23.46 | 2019 | |
| Ibsa Pharma INC. | $17.70 | 2022 | |
| Inspire Medical Systems, INC. | $15.31 | 2025 | Inspire |
| Siemens Medical Solutions USA, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.